KEI Submissions to the NIH on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning

The National Institutes of Health (NIH) Office of Science Policy (OSP) posted a Request for Information (RFI) on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning. The draft policy seeks, “to promote access to products stemming… Continue Reading

KEI comments on US Patent office RFC on “Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace”

Comments by Knowledge Ecology International, Regarding: Request for Comments: Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace, Notice by the Patent and Trademark Office on 03/15/2024, Document Citation: 89 FR 18907, Agency/Docket Number: Docket… Continue Reading

KEI Comment to NIST on Transparency of March-in Proceedings

On December 8, 2023, the National Institute of Standards and Technology (NIST) issued a Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593). Today KEI submitted comments to NIST regarding… Continue Reading

KEI and Public Citizen Joint Comments on NIH License to Leyden for Coronavirus Treatment

On November 3, 2023, Knowledge Ecology International (KEI) and Public Citizen (PC) submitted joint comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses” (88 FR… Continue Reading

Letter to FDA on the Cost to the Public of the Pediatric Trial Exclusivity Extension

Today, Knowledge Ecology International (KEI) submitted a letter to the Commissioner of the Food and Drug Administration (FDA) regarding the mismatch between the cost to perform pediatric extension trials and the cost to the public of the six month extension… Continue Reading

KEI Questions to the NIH Regarding Prospective License of T-cell Cancer Therapy to EnZeta Immunotherapies

(Update: The NIH provided a response to our questions on August 17, 2023.) On August 11, 2023, Knowledge Ecology International (KEI) submitted questions to the National Institutes of Health regarding the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution,… Continue Reading

KEI Comments to the NIH Regarding the Prospective Grant of an Exclusive License to Elgia Therapeutics

On Friday August 4, 2023, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors” (88 FR 47152) to Elgia Therapeutics, Inc.… Continue Reading

FTC asked to use its advocacy role in the Xtandi case

The U.S. Federal Trade Commission (FTC) mission “is protecting the public from deceptive or unfair business practices and from unfair methods of competition through law enforcement, advocacy, research, and education.” https://www.ftc.gov/about-ftc/mission The advocacy role of the FTC includes to “Advance… Continue Reading

Thursday webinar on Bayh-Dole safeguards including Xtandi march in and government use petition, and federal government review of march in rights

(UPDATE: A recording of the event is available on our YouTube channel here: https://www.youtube.com/watch?v=_qFgm-dohuU) Date: Thursday April 20, 2023 Time: 1:30 PM to 3:00 PM EDT Knowledge Ecology International is hosting an online discussion of two Bayh-Dole safeguard related topics.… Continue Reading